**This plan will expire after 365 days at which time a new order will need to be placed**

**GUIDELINES FOR ORDERING**

1. Send FACE SHEET and H&P or most recent chart note.
2. Hypersensitivity reactions have been reported, including generalized urticaria and serum sickness or serum sickness-like reactions. Discontinue dupilumab if clinically significant hypersensitivity reaction occurs.
3. Conjunctivitis and keratitis have been reported.
4. Avoid use of live vaccines in patients treated with dupilumab.

**MEDICATIONS:**

- dupilumab (DUPIXENT) injection, subcutaneous, ONCE

**Initial Dose:**

- □ 600 mg (given as two 300 mg injections)

**Maintenance Doses:**

- □ 300 mg, every 2 weeks for ____ doses

**NURSING ORDERS:**

1. Advise patient to report signs/symptoms of hypersensitivity, including urticaria or symptoms of serum sickness or serum sickness-like reactions.
2. Advise patient to report new onset or worsening eye symptoms, including conjunctivitis, keratitis, or blepharitis.
3. Advise patient with comorbid asthma not to adjust or discontinue asthma treatment without consultation with a physician.
4. Prior to administration, remove prefilled syringe from the refrigerator and allow to warm at room temperature for 45 minutes.
5. Administer subcutaneously into the upper arm, thigh, or abdomen (avoiding areas within 2 inches of navel). Rotate injection site with each injection. Do not inject into skin that is tender, damaged, bruised, or scarred.
6. Follow facility policies and/or protocols for vascular access maintenance with appropriate flush solution, declotting (alteplase), and/or dressing changes.
HYPERSENSITIVITY MEDICATIONS:
1. NURSING COMMUNICATION – If hypersensitivity or infusion reactions develop, temporarily hold the infusion and notify provider immediately. Administer emergency medications per the Treatment Algorithm for Acute Infusion Reaction (Policy HC-PAT-133-GUD). Refer to algorithm for symptom monitoring and continuously assess as grade of severity may progress.
2. diphenhydramINE (BENADRYL) injection, 25-50 mg, intravenous, AS NEEDED x1 dose for hypersensitivity reaction
3. EPINEPHrine HCl (ADRENALIN) injection, 0.3 mg, intramuscular, AS NEEDED x1 dose for hypersensitivity reaction
4. hydrocortisone sodium succinate (SOLU-CORTEF) injection, 100 mg, intravenous, AS NEEDED x 1 dose for hypersensitivity reaction
5. famotidine (PEPCID) injection, 20 mg, intravenous, AS NEEDED x1 dose for hypersensitivity reaction

By signing below, I represent the following:
I am responsible for the care of the patient (who is identified at the top of this form);
I hold an active, unrestricted license to practice medicine in: □ Oregon □ ______________________ (check box that corresponds with state where you provide care to patient and where you are currently licensed. Specify state if not Oregon);
My physician license Number is # ______________________ (MUST BE COMPLETED TO BE A VALID PRESCRIPTION); and I am acting within my scope of practice and authorized by law to order Infusion of the medication described above for the patient identified on this form.
OLC Central Intake Nurse:
Phone: 971-262-9645 (providers only) Fax: 503-346-8058

Please check the appropriate box for the patient's preferred clinic location:

☐ Beaverton
   OHSU Knight Cancer Institute
   15700 SW Greystone Court
   Beaverton, OR 97006
   Phone number: 971-262-9000
   Fax number: 503-346-8058

☐ NW Portland
   Legacy Good Samaritan campus
   Medical Office Building 3, Suite 150
   1130 NW 22nd Ave.
   Portland, OR 97210
   Phone number: 971-262-9600
   Fax number: 503-346-8058

☐ Gresham
   Legacy Mount Hood campus
   Medical Office Building 3, Suite 140
   24988 SE Stark
   Gresham, OR 97030
   Phone number: 971-262-9500
   Fax number: 503-346-8058

☐ Tualatin
   Legacy Meridian Park campus
   Medical Office Building 2, Suite 140
   19260 SW 65th Ave.
   Tualatin, OR 97062
   Phone number: 971-262-9700
   Fax number: 503-346-8058

Infusion orders located at: www.ohsuknight.com/infusionorders